GLP-1 drugs and midsize bodies: what the data actually shows

What did @midsizekelly actually say?

Kelly's core claim is straightforward: she has spent the majority of 13-14 months on tirzepatide at the starting 2.5mg weekly dose, with only about six weeks at 3.75mg, and reached her goal weight without ever going higher. She's pushing back on the assumption that dose escalation is mandatory, telling her followers "you don't have to move up each pen" if you're seeing results at a lower dose.

To be fair to her, she's also acknowledging the limits of her experience. She says clearly that "some people they have to move up the pens because that's just what works best." She's not telling everyone to stay at 2.5mg. She's describing her own journey and responding to a flood of DMs from people who didn't know staying at a lower dose was even an option.

Does the science back this up?

Partially, yes. Tirzepatide's dose escalation schedule is a protocol designed to minimize side effects, not a biological requirement for the drug to work. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) tested doses of 5mg, 10mg, and 15mg, and found weight loss was dose-dependent, meaning higher doses produced more weight loss on average. But "on average" is doing a lot of work in that sentence.

Individual response to GLP-1 and GIP receptor agonists varies considerably. Some patients achieve clinically meaningful weight loss at lower doses and experience diminishing returns, or intolerable side effects, at higher ones. The prescribing information for Zepbound lists 2.5mg as a starting dose intended for titration, but it does not set a mandatory ceiling timeline. A prescriber can, in clinical judgment, maintain a patient at any dose where they are responding and tolerating the medication.

• SURMOUNT-1 showed 5mg produced roughly 15% weight loss vs 20%+ at 15mg, but individual variance was wide.
• No published trial has specifically studied long-term maintenance at 2.5mg as an endpoint dose.

What did they get wrong (or right)?

She got the general principle right: dose escalation is a guideline, not a law. Where things get murky is her framing of the 2.5mg pen as something other than a titration tool. She pushes back on the "just a loading pen" characterization, which is fair in that it can be therapeutic, but the evidence base for long-term outcomes at 2.5mg specifically is thin. Most of what we know about tirzepatide's efficacy comes from trials that escalated patients to higher doses.

There's also a missing piece in her account: she doesn't mention whether she had medical supervision throughout this process. Staying at 2.5mg for 13 months without clinical monitoring is a different situation than doing so with a prescriber who is tracking biometrics, labs, and weight trajectory. Her audience may not make that distinction. That gap in context is a problem, not because her experience is wrong, but because it could lead someone to self-direct their dose decisions without professional input.

What should you actually know?

Your dose should be determined by your response and your prescriber's assessment, not by a default escalation calendar or by what worked for someone else on TikTok. That goes both ways: if you're tolerating a low dose well and losing weight, there is no clinical rule that forces you to go higher. If you've plateaued and aren't meeting your goals, staying at 2.5mg indefinitely may not serve you.

What matters clinically is whether you are achieving meaningful weight reduction, tolerating the medication, and doing so under medical supervision. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) demonstrated that continuing tirzepatide after initial weight loss prevents regain, but that data was built on participants who had reached maintenance doses. There is no equivalent long-term data for patients who stayed at 2.5mg throughout.

If you are on a GLP-1 or GIP receptor agonist and have questions about your dose, talk to your prescriber. A TikTok creator's 13-month anecdote, however genuine, is not a substitute for a clinical conversation about your individual metabolic response.